Our Product Pricing

Reason for Proposed 2025 Price Increase: Mallinckrodt is increasing the list price of Acthar® Gel by 3% on January 1, 2025. The Brand's price increase is below the rate of the Consumer Price Index inflation, and Mallinckrodt believes its pricing strategy reflects the benefits Acthar® Gel brings to patients and society. The company is committed to ensuring appropriate patients have access to therapy, and Mallinckrodt continues to invest to achieve that goal. Key areas of investment include research and development, bringing Acthar® Gel Single-Dose Pre-filled SelfJect™ Injector to market and investing in appropriate staffing for our patient assistance programs. The last pricing action taken by Mallinckrodt on Acthar® Gel was a 3% increase in January 2024.  Acthar’s list price is not reflective of the significant, and annually increasing, discounts frequently available to customers.

*Reason for Proposed 2024 Price Increase: No change in price, table update only reflecting the launch of two new SKUs. The new SKUs are at price parity to the existing SKU.

Reason for Proposed 2024 Price Increase: Mallinckrodt is increasing the list price of Acthar® Gel by 3% on January 1, 2024. The Brand's price increase is below the rate of the Consumer Price Index inflation, and Mallinckrodt believes its pricing strategy reflects the benefits Acthar® brings to patients and society. The company is committed to ensuring appropriate patients have access to therapy, and Mallinckrodt continues to invest to achieve that goal. Key areas of investment include bringing a new delivery solution to market, as well as improving robustness of supply. The last pricing action taken by Mallinckrodt on Acthar was a 3% increase in January 2023.  Acthar’s list price is not reflective of the significant, and annually increasing, discounts frequently available to customers.

Reason for Proposed 2023 Price Increase: Mallinckrodt is increasing the list price of Acthar® Gel by 3% on January 2, 2023. This price increase is a result of continued product innovation and increased costs incurred by Mallinckrodt to operate the business. This falls below the Consumer Price Index. The last pricing action taken by Mallinckrodt on Acthar was a 4% increase in 2022. Acthar’s list price is not reflective of significant discounts frequently available to customers.

Reason for Proposed 2022 Price Increase: Mallinckrodt is increasing the list price of Acthar® Gel by 4% on February 1, 2022, the first price increase for Acthar in more than two years. Acthar’s list price does not reflect significant discounts often available to customers. This increase is the result of increased costs and other financial commitments of the company, including the recent launch of a new biologic therapy to treat adults with deep partial-thickness burns and the potential launch of another therapy later this year. Since owning Acthar, Mallinckrodt has invested more than $650 million to modernize and validate Acthar for use with appropriate patients through further studies that evaluated the safety and efficacy of Acthar within our indications and modernizing the analytical testing and manufacturing processes. The last pricing action taken by Mallinckrodt on Acthar was a 2.5% increase in 2019.